CompletedNot Applicable

The Role of GIP and GLP-2 in Postprandial Splanchnic Blood Flow Distribution and Metabolism

Denmark10 participantsStarted 2022-01-13

Plain-language summary

This project will describe the mechanisms of action and the relative contributions of GIP and GLP-2 to changes in gastrointestinal blood flow induced by oral glucose, exogenous GIP and GLP-2 infusions, and endogenous GIP and GLP-2 with the use of two novel receptor antagonists GIP(3-30)NH2 and GLP-2(3-33) in healthy individuals.

Who can participate

Age range20 Years – 70 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * No first degree relatives with diabetes * BMI 20-27 kg/m2 Exclusion Criteria: * Not MRI-compatible implants * Claustrophobia * Diabetes * Abnormal kidney or liver function * Anemia * Planned weight loss or change in diet * Hypertension * Other conditions that could be expected to affect the primary or secondary outcomes

What they're measuring

Redistribution of splanchnic blood flow (functional MRI)

Timeframe: 90 minutes

Trial details

NCT IDNCT05391581

SponsorUniversity of Copenhagen

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-02-07

View on ClinicalTrials.gov More Blood Flow trials